Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Osteoporosis: HELP
Articles by Mette Haase Moen
Based on 4 articles published since 2010
(Why 4 articles?)

Between 2010 and 2020, Mette H. Moen wrote the following 4 articles about Osteoporosis.
+ Citations + Abstracts
1 Guideline EMAS position statement: Bone densitometry screening for osteoporosis. 2011

Brincat, Mark / Calleja-Agius, Jean / Erel, C Tamer / Gambacciani, Marco / Lambrinoudaki, Irene / Moen, Mette H / Schenck-Gustafsson, Karin / Tremollieres, Florence / Vujovic, Svetlana / Rees, Margaret / Rozenberg, Serge / Anonymous5800679. ·Department of Obstetrics and Gynaecology, Mater Dei Hospital, BKR 2090 B’Kara, Malta. brincatm@maltanet.net ·Maturitas · Pubmed #21093180.

ABSTRACT: INTRODUCTION: Osteoporosis and its consequent fractures is a major public health problem. AIM: To formulate a position statement on the use of bone densitometry in screening postmenopausal women for osteoporosis and in their management. MATERIALS AND METHODS: Literature review and consensus of expert opinion. RESULTS AND CONCLUSIONS: Bone densitometry has an important role in screening postmenopausal women for osteoporosis. For higher sensitivity and specificity, there may be a stronger case for screening in later life, depending on the extent to which risk factors add to the value of bone mineral density tests.

2 Review New developments in the treatment of osteoporosis. 2013

Eriksen, Erik Fink / Halse, Johan / Moen, Mette Haase. ·Department of Clinical Endocrinology, Oslo University Hospital, Aker, Oslo, Norway. e.f.eriksen@medisin.uio.no ·Acta Obstet Gynecol Scand · Pubmed #22646526.

ABSTRACT: The last 25 years have seen the development of a plethora of new, effective agents for the treatment of osteoporosis. These agents reduce the risk of spine fractures by up to 70%, hip fractures by 40-50% and non-vertebral fractures by up to 50-80%. Amino-bisphosphonates, taken orally or intravenously, remain the dominant treatment modalities for osteoporosis. These so-called anti-resorptive or anti-catabolic agents stabilize the skeleton and reduce fracture risk in osteoporotic as well as osteopenic individuals. A monoclonal antibody against receptor activator of nuclear factor κB ligand, Denosumab, constitutes a new anti-resorptive agent recently approved worldwide. In younger postmenopausal women, low-dose estrogen or estrogen/progestin still has a place for short-term (up to 5 years) preservation of bone mass, especially in women with menopausal symptoms. Likewise, selective estrogen receptor modulators should be considered in younger postmenopausal women, especially those at increased risk of breast cancer. Anabolic (bone forming) regimens, of which parathyroid hormone is the only agent currently available, aid in the build up of new bone, increase bone mass and improve bone architecture. In cancellous bone, 30-60% increases of bone mass have been documented, but cortical bone thickness also increases. These improvements lead to profound reduction in fracture rates in both the axial and appendicular skeleton. Owing to cost and the need for parenteral administration, in most countries these agents are reserved for severe osteoporosis with multiple fractures.

3 Review EMAS clinical guide: selective estrogen receptor modulators for postmenopausal osteoporosis. 2012

Palacios, Santiago / Brincat, Mark / Erel, C Tamer / Gambacciani, Marco / Lambrinoudaki, Irene / Moen, Mette H / Schenck-Gustafsson, Karin / Tremollieres, Florence / Vujovic, Svetlana / Rees, Margaret / Rozenberg, Serge. ·Palacios Institute of Woman's Health Antonio Acuna, Madrid, Spain. ipalacios@institutopalacios.com ·Maturitas · Pubmed #22176952.

ABSTRACT: Osteoporosis and the resulting fractures are major public health issues as the world population is ageing. Various therapies such as bisphosphonates, strontium ranelate and more recently denosumab are available. This clinical guide provides the evidence for the clinical use of selective estrogen modulators (SERMs) in the management of osteoporosis in postmenopausal women.

4 Article [Estrogens in menopause – time to change the guidelines?]. 2018

Eriksen, Erik Fink / Moen, Mette Haase / Iversen, Ole Erik. · ·Tidsskr Nor Laegeforen · Pubmed #29557135.

ABSTRACT: -- No abstract --